Patents by Inventor Charlotte BEAU-LARVOR
Charlotte BEAU-LARVOR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11661457Abstract: The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.Type: GrantFiled: February 26, 2020Date of Patent: May 30, 2023Assignee: PIERRE FABRE MEDICAMENTInventors: Ian Rilatt, Michel Perez, Liliane Goetsch, Matthieu Broussas, Charlotte Beau-Larvor, Jean-Francois Haeuw, Thierry Champion, Alain Robert, Marie Lamothe
-
Patent number: 11365259Abstract: The present invention relates to an antibody, in particular a monoclonal antibody, capable of binding to IGF-1R, as well as the amino and nucleic acid sequences coding for said antibody. From one aspect, the invention relates to an antibody, or an antigen binding fragment thereof, capable of binding to IGF-1R and, by inducing internalization of IGF-1R, being internalized into the cell. The invention also comprises the use of said antibody as an addressing product or vehicle in conjugation with other anti-cancer compounds such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.Type: GrantFiled: December 18, 2018Date of Patent: June 21, 2022Assignee: PIERRE FABRE MEDICAMENTInventors: Liliane Goetsch, Matthieu Broussas, Charlotte Beau-Larvor, Thierry Champion, Alain Robert
-
Publication number: 20220105195Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.Type: ApplicationFiled: November 15, 2021Publication date: April 7, 2022Applicant: PIERRE FABRE MEDICAMENTInventors: Ian RILATT, Michel PEREZ, Liliane GOETSCH, Matthieu BROUSSAS, Charlotte BEAU-LARVOR, Jean-François HAEUW, Marie LAMOTHE
-
Patent number: 11219693Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an anti-body-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drag selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said anti-body-drag-conjugate for the treatment of cancer.Type: GrantFiled: April 16, 2019Date of Patent: January 11, 2022Assignee: PIERRE FABRE MEDICAMENTInventors: Ian Rilatt, Michel Perez, Liliane Goetsch, Matthieu Broussas, Charlotte Beau-Larvor, Jean-François Haeuw, Marie Lamothe
-
Publication number: 20210038738Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an anti-body-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.Type: ApplicationFiled: October 28, 2020Publication date: February 11, 2021Applicant: PIERRE FABRE MEDICAMENTInventors: Ian RILATT, Michel Perez, Liliane Goetsch, Matthieu Broussas, Charlotte Beau-Larvor, Jean-Francois Haeuw, Marie Lamothe
-
Patent number: 10858423Abstract: The present invention relates to a method for the treatment of IGF-IR expressing cancers as well as to a compositions and a kit for said traitment. From one aspect, the invention relates to the combined use of a first antibody for the determination of the IGF-IR status of a cancer and a second antibody used as an ADC for the treatment of said cancer.Type: GrantFiled: October 26, 2016Date of Patent: December 8, 2020Assignee: PIERRE FABRE MEDICAMENTInventors: Alexandra Jouhanneaud, Liliane Goetsch, Matthieu Broussas, Charlotte Beau-Larvor, Thierry Champion, Alain Robert, Jean-François Haeuw, Ian Rilatt, Michel Perez, Marie Lamothe
-
Publication number: 20200270352Abstract: The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.Type: ApplicationFiled: February 26, 2020Publication date: August 27, 2020Applicant: PIERRE FABRE MEDICAMENTInventors: Ian RILATT, Michel PEREZ, Liliane GOETSCH, Matthieu BROUSSAS, Charlotte BEAU-LARVOR, Jean-Francois HAEUW, Thierry CHAMPION, Alain ROBERT, Marie LAMOTHE
-
Patent number: 10633448Abstract: The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.Type: GrantFiled: April 27, 2015Date of Patent: April 28, 2020Assignee: PIERRE FABRE MEDICAMENTInventors: Ian Rilatt, Michel Perez, Liliane Goetsch, Matthieu Broussas, Charlotte Beau-Larvor, Jean-Francois Haeuw, Thierry Champion, Alain Robert, Marie Lamothe
-
Publication number: 20190330353Abstract: The present invention relates to an antibody, in particular a monoclonal antibody, capable of binding to IGF-1R, as well as the amino and nucleic acid sequences coding for said antibody. From one aspect, the invention relates to an antibody, or an antigen binding fragment thereof, capable of binding to IGF-1R and, by inducing internalization of IGF-1R, being internalized into the cell. The invention also comprises the use of said antibody as an addressing product or vehicle in conjugation with other anti-cancer compounds such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.Type: ApplicationFiled: December 18, 2018Publication date: October 31, 2019Applicant: PIERRE FABRE MEDICAMENTInventors: Liliane GOETSCH, Matthieu Broussas, Charlotte BEAU-LARVOR, Thierry Champion, Alain Robert
-
Publication number: 20190269788Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.Type: ApplicationFiled: April 16, 2019Publication date: September 5, 2019Applicant: PIERRE FABRE MEDICAMENTInventors: Ian RILATT, Michel PEREZ, Liliane GOETSCH, Matthieu BROUSSAS, Charlotte BEAU-LARVOR, Jean-François HAEUW, Marie LAMOTHE
-
Publication number: 20190202901Abstract: The present invention relates to a method for the treatment of IGF-IR expressing cancers as well as to a compositions and a kit for said traitment. From one aspect, the invention relates to the combined use of a first antibody for the determination of the IGF-IR status of a cancer and a second antibody used as an ADC for the treatment of said cancer.Type: ApplicationFiled: October 26, 2016Publication date: July 4, 2019Inventors: Alexandra JOUHANNEAUD, Liliane GOETSCH, Matthieu BROUSSAS, Charlotte BEAU-LARVOR, Thierry CHAMPION, Robert ALAIN, Jean-François HAEUW, Ian RILATT, Michel PEREZ
-
Patent number: 10314921Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.Type: GrantFiled: April 27, 2015Date of Patent: June 11, 2019Assignee: PIERRE FABRE MEDICAMENTInventors: Ian Rilatt, Michel Perez, Liliane Goetsch, Matthieu Broussas, Charlotte Beau-Larvor, Jean-Francois Haeuw, Marie Lamothe
-
Patent number: 10202458Abstract: The present invention relates to an antibody, in particular a monoclonal antibody, capable of binding to IGF-1R, as well as the amino and nucleic acid sequences coding for said antibody. From one aspect, the invention relates to an antibody, or an antigen binding fragment thereof, capable of binding to IGF-1R and, by inducing internalization of IGF-1R, being internalized into the cell. The invention also comprises the use of said antibody as an addressing product or vehicle in conjugation with other anti-cancer compounds such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.Type: GrantFiled: April 27, 2015Date of Patent: February 12, 2019Assignee: PIERRE FABRE MEDICAMENTInventors: Liliane Goetsch, Matthieu Broussas, Charlotte Beau-Larvor, Thierry Champion, Alain Robert
-
Patent number: 10161930Abstract: The present invention relates to a novel antigen binding protein, in particular a monoclonal antibody, capable of binding specifically to the protein Axl as well as the amino and nucleic acid sequences coding for said protein. From one aspect, the invention relates to a novel antigen binding protein, or antigen binding fragments, capable of binding specifically to Axl and, by inducing internalization of Axl, being internalized into the cell. The invention also comprises the use of said antigen binding protein as an addressing product in conjugation with other anti-cancer compounds, such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.Type: GrantFiled: September 16, 2015Date of Patent: December 25, 2018Assignee: PIERRE FABRE MEDICAMENTInventors: Charlotte Beau-Larvor, Liliane Goetsch
-
Publication number: 20180228915Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.Type: ApplicationFiled: January 31, 2018Publication date: August 16, 2018Inventors: Ian RILATT, Michel PEREZ, Liliane GOETSCH, Matthieu BROUSSAS, Charlotte BEAU-LARVOR, Jean-Francois HAEUW
-
Publication number: 20170267766Abstract: The present invention relates to an antibody, in particular a monoclonal antibody, capable of binding to IGF-1R, as well as the amino and nucleic acid sequences coding for said antibody. From one aspect, the invention relates to an antibody, or an antigen binding fragment thereof, capable of binding to IGF-1R and, by inducing internalization of IGF-1R, being internalized into the cell. The invention also comprises the use of said antibody as an addressing product or vehicle in conjugation with other anti-cancer compounds such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.Type: ApplicationFiled: April 27, 2015Publication date: September 21, 2017Applicant: PIERRE FABRE MEDICAMENTInventors: Liliane GOETSCH, Matthleu BROUSSAS, Charlotte BEAU-LARVOR, Thierry CHAMPION, Alain ROBERT
-
Patent number: 9689862Abstract: The present invention relates to an antigen binding protein, in particular a monoclonal antibody, capable of binding specifically to the protein Axl as well as the amino and nucleic acid sequences coding for said protein. From one aspect, the invention relates to an antigen binding protein, or antigen binding fragments, capable of binding specifically to Axl and, by inducing internalization of Axl, being internalized into the cell. The invention also comprises the use of said antigen binding protein as an addressing product in conjugation with other anti-cancer compounds, such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.Type: GrantFiled: November 5, 2012Date of Patent: June 27, 2017Assignee: PEIRRE FABRE MEDICAMENTInventors: Charlotte Beau-Larvor, Liliane Goetsch, Nicolas Boute
-
Patent number: 9624308Abstract: The present invention relates to novel antigen binding proteins, in particular monoclonal antibodies, capable of binding to the protein Axl as well as the amino and nucleic acid sequences coding for said proteins. From one aspect, the invention relates to novel antigen binding proteins, or antigen binding fragments, capable of binding to Axl and, by inducing internalization of Axl, being internalized into the cell. The invention also comprises the use of said antigen binding proteins as addressing products in conjugation with other anti-cancer compounds, such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.Type: GrantFiled: November 5, 2013Date of Patent: April 18, 2017Assignee: PIERRE FABRE MEDICAMENTInventors: Charlotte Beau-Larvor, Liliane Goetsch, Nicolas Boute
-
Publication number: 20170043032Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.Type: ApplicationFiled: April 27, 2015Publication date: February 16, 2017Applicant: PIERRE FABRE MEDICAMENTInventors: Ian RILATT, Michel PEREZ, Liliane GOETSCH, Matthieu BROUSSAS, Charlotte BEAU-LARVOR, Jean-Francois HAEUW
-
Publication number: 20170043031Abstract: The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.Type: ApplicationFiled: April 27, 2015Publication date: February 16, 2017Applicant: PIERRE FABRE MEDICAMENTInventors: Ian RILATT, Michel PEREZ, Liliane GOETSCH, Mathieu BROUSSAS, Charlotte BEAU-LARVOR, Jean-Francois HAEUW, Thierry CHAMPION, Alain ROBERT